Drug Trial Radar · NCT00982111
First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin
Last checked: Nov 20, 2026Latest source record: Jan 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
633
Actual
Start
Nov 2, 2009
Primary completion
Nov 14, 2012
Study completion Dec 23, 2020
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- Collaborators
- Quintiles, Inc.; Parexel; PPD Development, LP; Medidata Solutions; Laboratory Corporation of America; University of Colorado, Denver; Thermo Fisher Scientific, Inc; Pacific Biomarkers; Intertek; Sysmex Inostics GmbH
- First posted
- Sep 22, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The research study is testing the investigational drug necitumumab in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and pemetrexed will be more effective in improving participant disease than the standard chemotherapy combination alone.
Conditions
- Non Small Cell Lung Cancer
Interventions
PemetrexedDrug
500 milligram per square meter (mg/m2) administered Intravenously (I.V.) on Day 1 of every 3-week cycle, for a maximum of six cycles
CisplatinDrug
75 mg/m2 administered I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles
NecitumumabBiological
800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival Time (OS)Time frame: Randomization to Death from Any Cause (Up to 31.6 Months)
Locations
101 sites in 20 countries. Site status is shown where the registry gives one.
ImClone Investigational Site
Nyack, New York
ImClone Investigational Site
Kogarah, New South Wales, Australia
ImClone Investigational Site
Hobart, Tasmania, Australia
ImClone Investigational Site
East Bentleigh, Victoria, Australia
ImClone Investigational Site
Rankweil, Austria
ImClone Investigational Site
Vienna, Austria
ImClone Investigational Site
Vienna, Austria
ImClone Investigational Site
Duffel, Belgium
ImClone Investigational Site
Liège, Belgium
ImClone Investigational Site
Namur, Belgium
ImClone Investigational Site
Barretos - SP, Brazil
ImClone Investigational Site
Brasilia, Distrito Federal, Brazil
ImClone Investigational Site
Goiania - GO, Brazil
ImClone Investigational Site
Ijuí, Brazil
ImClone Investigational Site
Itajaí, Brazil
ImClone Investigational Site
Lajeado, Brazil
ImClone Investigational Site
Porto Alegre/RS, Brazil
ImClone Investigational Site
Ribeirão Preto - SP, Brazil
ImClone Investigational Site
Salvador, Brazil
ImClone Investigational Site
Santo Andre - SP, Brazil
ImClone Investigational Site
São Paulo - SP, Brazil
ImClone Investigational Site
Montreal, Quebec, Canada
ImClone Investigational Site
Pula, Croatia
ImClone Investigational Site
Caen, France
ImClone Investigational Site
Paris, France
ImClone Investigational Site
Berlin, Germany
ImClone Investigational Site
Essen, Germany
ImClone Investigational Site
Frankfurt, Germany
ImClone Investigational Site
Gauting, Germany
ImClone Investigational Site
Großhansdorf, Germany
ImClone Investigational Site
Halle, Germany
ImClone Investigational Site
Hamburg, Germany
ImClone Investigational Site
Heidelberg, Germany
ImClone Investigational Site
Hemer, Germany
ImClone Investigational Site
Hofheim, Germany
ImClone Investigational Site
Karlsruhe, Germany
ImClone Investigational Site
Lostau, Germany
ImClone Investigational Site
Löwenstein, Germany
ImClone Investigational Site
Mainz, Germany
ImClone Investigational Site
München, Germany
Showing 40 of 101 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.